StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright reaffirmed a buy rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $9.00.
Read Our Latest Research Report on APTO
Aptose Biosciences Stock Up 1.3 %
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.15. As a group, analysts expect that Aptose Biosciences will post -2.62 earnings per share for the current year.
Institutional Trading of Aptose Biosciences
An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by hedge funds and other institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Articles
- Five stocks we like better than Aptose Biosciences
- What is the Euro STOXX 50 Index?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.